PRESS RELEASE
For Immediate release
May 29, 2019

Veana Starts Second Clinical Trial
1 in 8 women will develop breast cancer in their lifetime. In 2018, 2.1 million women worldwide were diagnosed with breast cancer and more than half a million died from the disease. The treatments for these patients, which include chemotherapy and radiation are very toxic, have significant long-term side effects and are not very effective in eliminating the cancer.

Veana Therapeutics recently received FDA approval to conduct a first-in-human clinical trial of its lead product, VIMO-001, an oral capsule, in combination with Herceptin™ in HER2 positive breast cancer patients that have failed all previous curative therapies. This is a significant accomplishment for Veana as very few companies of our size achieve this goal this early in their development.

The combination clinical trial will be conducted in partnership with the University of Washington/Fred Hutchinson Cancer Research Center in Seattle under the direction of Mary (Nora) Disis, M.D., an outstanding oncologist and internationally recognized leader in the field of breast cancer treatment. The capsules are currently being manufactured and the Cancer Center is gearing up to start enrolling patients beginning next month.

Contact information:
Emmanuel Akporiaye, Ph.D.
Veana Therapeutics, Portland, OR
veana-therapeutics.com
info@veana-therapeutics.com
Tel: 503-869-0983